About Freenome
Freenome is a biotechnology company with a comprehensive multiomics platform for cancer detection using a routine blood draw.
Headquarters
Freenome, South San Francisco
Founded
2014-01-01
Industry
Biotechnology, Health Care, Health Diagnostics, Personal Health
Last Funding Type
Series Unknown
Valuation
1
Total Funding
$1.35 billion dollars
IPO Status
Private
Financial
Freenome announced positive results for its blood-based test for early detection of colorectal cancer, achieving 79.2% sensitivity and 91.5% specificity. Concurrently, the company is reducing its workforce by about 20%, impacting over 100 employees, as part of a restructuring effort. Additionally, Freenome recently secured $254 million in funding, underscoring its ongoing commitment to cancer detection research.
Funding Rounds
9
Number of Lead Investors
8
Total Funding Amount
$1.35 billion dollars
Number of Investors
54